{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:16:05Z","timestamp":1791234965863,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.cellimm.2013.11.003","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T07:20:10Z","timestamp":1385018410000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Crohn\u2019s disease: A review of treatment options and current research"],"prefix":"10.1016","volume":"286","author":[{"given":"Sean","family":"Bandzar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu O.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2013.11.003_b0005","unstructured":"Anonymous, Crohn\u2019s and colitis foundation of America, explore CCFA research (2010). Available from: <http:\/\/www.ccfa.org\/research\/?LMI=7>."},{"key":"10.1016\/j.cellimm.2013.11.003_b0010","unstructured":"Mayo Clinic Staff, Mayo Clinic, Crohn\u2019s disease: Symptoms. Available from: <http:\/\/www.mayoclinic.com\/health\/crohnsdisease\/DS00104\/DSECTION=symptoms>."},{"key":"10.1016\/j.cellimm.2013.11.003_b0015","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0016-5085(75)80270-8","article-title":"Clinical patterns in Crohn\u2019s disease: a statistical study of 615 cases","volume":"68","author":"Farmer","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0020","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3748\/wjg.v11.i20.3118","article-title":"Clinical significance of granuloma in Crohn\u2019s disease","volume":"20","author":"Molnar","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0033-8389(02)00117-3","article-title":"Classification of small bowel Crohn\u2019s subtypes based on multimodality imaging","volume":"41","author":"Maglinte","year":"2003","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.cellimm.2013.11.003_b0030","first-page":"C4338","article-title":"Diagnosis and treatment of fistulising Crohn\u2019s disease","volume":"58","author":"Hvas","year":"2011","journal-title":"Danish Med. J."},{"key":"10.1016\/j.cellimm.2013.11.003_b0035","first-page":"55","article-title":"Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations","volume":"9","author":"Evans","year":"2007","journal-title":"Med. Gen. Med."},{"key":"10.1016\/j.cellimm.2013.11.003_b0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mpd.2002.125907","article-title":"Self-assessment of sexual maturity status in children with Crohn\u2019s disease","volume":"141","author":"Schall","year":"2002","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0045","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/gut.2008.162495","article-title":"Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn\u2019s disease","volume":"58","author":"Roggenbuck","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0050","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1189\/jlb.0405188","article-title":"Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn\u2019s disease","volume":"79","author":"Carol","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/gut.49.1.35","article-title":"Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn\u2019s disease","volume":"49","author":"Itoh","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0060","first-page":"72","article-title":"Interleukin-17 in chronic inflammatory and autoimmune diseases: rheumatoid arthritis, Crohn\u2019s disease and Wegener\u2019s granulomatosis","volume":"67","author":"Muller","year":"2008","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"10.1016\/j.cellimm.2013.11.003_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.MIB.0000194183.92671.b6","article-title":"Both IL-12p70 and IL-23 are synthesized during active Crohn\u2019s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody","volume":"12","author":"Fuss","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cellimm.2013.11.003_b0070","first-page":"203","article-title":"Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis","volume":"39","author":"Ruemmele","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0075","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1172\/JCI35179","article-title":"The comeback kid: Tysabri now FDA approved for Crohn\u2019s disease","volume":"118","author":"Honey","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2013.11.003_b0080","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.2165\/00003495-200767170-00005","article-title":"Crohn\u2019s disease: a review of current treatment with a focus on biologics","volume":"67","author":"Panes","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.cellimm.2013.11.003_b0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/pch\/9.2.87","article-title":"Infliximab for the treatment of paediatric Crohn\u2019s disease: obstacles to accessing a necessary therapy","volume":"9","author":"Otley","year":"2004","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.cellimm.2013.11.003_b0090","first-page":"1406","article-title":"Adalimumab (Humira) for the treatment of rheumatoid arthritis","volume":"78","author":"Welch","year":"2008","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.cellimm.2013.11.003_b0095","unstructured":"Johnson and Johnson pharmaceutical research and development. ClincalTrials.gov. Natl. Lib. Med. (2013). Available from: <http:\/\/clinicaltrials.gov\/show\/NCT01369355> NLM Identifier: NCT01369355."},{"key":"10.1016\/j.cellimm.2013.11.003_b0100","unstructured":"Amgen. ClincalTrials.gov. Natl. Lib. Med. (2013). Available from: <http:\/\/clinicaltrials.gov\/show\/NCT01150890> NLM Identifier: NCT01150890."},{"key":"10.1016\/j.cellimm.2013.11.003_b0105","unstructured":"Amgen. ClincalTrials.gov. Natl. Lib. Med. (2013). Available from: <http:\/\/clinicaltrials.gov\/show\/NCT01258205> NLM Identifier: NCT01258205."},{"key":"10.1016\/j.cellimm.2013.11.003_b0110","first-page":"989","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s disease","volume":"125","author":"Hiroaki","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0115","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti\u2013interleukin-12 antibody for active Crohn\u2019s disease","volume":"351","author":"Mannon","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cellimm.2013.11.003_b0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reuma.2011.08.002","article-title":"Abatacept mechanism of action: concordance with its clinical profile","volume":"8","author":"Herrero-Beaumont","year":"2012","journal-title":"Reumatologia Clinica"},{"key":"10.1016\/j.cellimm.2013.11.003_b0125","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0130","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","article-title":"Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease","volume":"119","author":"Schreiber","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0135","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/gast.1997.v113.pm9247454","article-title":"Multiple doses of intravenous interleukin 10 in steroid- refractory Crohn\u2019s disease","volume":"113","author":"Van Deventer","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0002-9440(10)65552-6","article-title":"In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease","volume":"153","author":"Autschbach","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0145","first-page":"CD005109","article-title":"Recombinant human interleukin 10 for induction of remission in Crohn\u2019s disease","author":"Buruiana","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cellimm.2013.11.003_b0150","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1572-0241.2005.00356.x","article-title":"Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn\u2019s disease","volume":"101","author":"Herrlinger","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","article-title":"Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn\u2019s disease","volume":"117","author":"Sands","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/dkg318","article-title":"Susceptibility to rifaximin of Vibrio Cholerae strains from different geographical area","volume":"52","author":"Scrascia","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cellimm.2013.11.003_b0165","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2174\/138161212799504858","article-title":"Non-systemic drugs: a critical review","volume":"18","author":"Charmot","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cellimm.2013.11.003_b0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10620-009-1111-y","article-title":"Adjunctive antibiotic therapy with rifaximin may help reduce Crohn\u2019s disease activity","volume":"4","author":"Shafran","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cellimm.2013.11.003_b0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cellimm.2013.11.003_b0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1381612033391900","article-title":"Anti-interleukin-6 therapy for Crohn\u2019s disease","volume":"9","author":"Ito","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cellimm.2013.11.003_b0185","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cellimm.2013.11.003_b0190","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1182\/blood.V90.7.2772","article-title":"Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirements for TNF-R55 and TNF-R75 for induction of apoptosis in vitro","volume":"90","author":"Murray","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2013.11.003_b0195","doi-asserted-by":"crossref","first-page":"G612","DOI":"10.1152\/ajpgi.90576.2008","article-title":"Infliximab and the TNF-alpha system","volume":"296","author":"Ebert","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0200","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cellimm.2013.11.003_b0205","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/emboj\/16.5.1080","article-title":"Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2","volume":"16","author":"Reinhard","year":"1997","journal-title":"The EMBO J."},{"key":"10.1016\/j.cellimm.2013.11.003_b0210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00063030-200620050-00005","article-title":"Adalimumab: a review of its use in adult patients with rheumatoid arthritis","volume":"20","author":"Cvetkovic","year":"2006","journal-title":"BioDrugs"},{"key":"10.1016\/j.cellimm.2013.11.003_b0215","first-page":"93","article-title":"Drug focus: adalimumab in the treatment of moderate to severe psoriasis","volume":"1","author":"Vena","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.cellimm.2013.11.003_b0220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrd2813","article-title":"2008 FDA drug approvals","volume":"8","author":"Hughes","year":"2008","journal-title":"Nat. Rev. Drug Dis."},{"key":"10.1016\/j.cellimm.2013.11.003_b0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gut.53.1.70","article-title":"Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn\u2019s disease","volume":"53","author":"Di Sabatino","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0230","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ddr.20470","article-title":"Certolizumab pegol therapy for rheumatoid arthritis: overview","volume":"72","author":"Zidi","year":"2011","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.cellimm.2013.11.003_b0235","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-alpha 4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"65","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0240","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1073\/pnas.88.18.8072","article-title":"Two integrin binding peptides abrogate T-cell mediated immune responses in vivo","volume":"88","author":"Ferguson","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cellimm.2013.11.003_b0245","doi-asserted-by":"crossref","first-page":"24655","DOI":"10.1016\/S0021-9258(19)74516-5","article-title":"VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin","volume":"268","author":"Chan","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2013.11.003_b0250","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri2532","article-title":"Intravascular immunity: the host-pathogen encounter in blood vessels","volume":"9","author":"Hickey","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0255","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0190-9622(03)01143-5","article-title":"Infliximab for psoriasis","volume":"49","author":"Gottlieb","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0260","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.BRS.0000058944.38900.CE","article-title":"Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica","volume":"28","author":"Karppinen","year":"2003","journal-title":"Spine"},{"key":"10.1016\/j.cellimm.2013.11.003_b0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cellimm.2013.11.003_b0270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/09546630410017284","article-title":"Adalimumab (Humira): a brief review for dermatologists","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.cellimm.2013.11.003_b0275","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cellimm.2013.11.003_b0280","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0285","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ajg.2008.138","article-title":"Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn\u2019s disease","volume":"104","author":"Baumgart","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn\u2019s disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0295","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4049\/jimmunol.0902007","article-title":"Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype","volume":"185","author":"Ghannem","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0300","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","article-title":"Immunomodulatory properties of mesenchymal stromal cells","volume":"110","author":"Nauta","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2013.11.003_b0305","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/gut.2010.215152","article-title":"Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn\u2019s disease: results of a phase I study","volume":"59","author":"Duijvestein","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0310","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.2010.214841","article-title":"A phase I clinical trial of the treatment of Crohn\u2019s disease","volume":"60","author":"Ciccocioppo","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0315","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/gut.2010.235507","article-title":"Mesenchymal stem cell therapy of Crohn\u2019s disease: are the far-away hills getting closer?","volume":"60","author":"Panes","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cellimm.2013.11.003_b0320","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPG.0b013e3181c992d6","article-title":"A randomized controlled trial of growth hormone in active pediatric Crohn\u2019s disease","volume":"51","author":"Denson","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0325","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.clnu.2012.03.002","article-title":"Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn\u2019s disease","volume":"31","author":"Bassaganya-Riera","year":"2012","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0330","unstructured":"Lee S, Induction of clinical response using rifaximin in Crohn\u2019s disease. ClinicalTrials.gov. Natl. Lib. Med. (2012). Available from: <http:\/\/clinicaltrials.gov\/show\/NCT00603616> NLM Identifier: NCT00603616."},{"key":"10.1016\/j.cellimm.2013.11.003_b0335","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cellimm.2013.11.003_b0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2012.07.084","article-title":"Mo2083 a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn\u2019s disease","volume":"143","author":"Targan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2009.313","article-title":"Interleukin-6 as a therapeutic target in candidate inflammatory disease","volume":"87","author":"Nishimoto","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cellimm.2013.11.003_b0350","unstructured":"Drug enforcement administration human growth hormone (2011). Available from: <http:\/\/www.deadiversion.usdoj.gov\/drugs_concern\/hgh.pdf>."},{"key":"10.1016\/j.cellimm.2013.11.003_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.93.1.1","article-title":"Binding in the growth hormone receptor complex","volume":"93","author":"Wells","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2013.11.003_b0360","first-page":"367","article-title":"Growth hormone signaling pathways","volume":"52","author":"Zych","year":"2006","journal-title":"Postepy Biochem."},{"key":"10.1016\/j.cellimm.2013.11.003_b0365","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrgastro.2009.124","article-title":"Mechanisms of growth impairment in pediatric Crohn\u2019s disease","volume":"6","author":"Walters","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0370","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.MIB.0000159321.58773.a6","article-title":"Effect of recombinant growth hormone treatment on children with Crohn\u2019s disease and short stature: a pilot study","volume":"11","author":"Calenda","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cellimm.2013.11.003_b0375","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1677\/JOE-09-0211","article-title":"Improving the pharmacokinetics\/ pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide","volume":"203","author":"Langenheim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0380","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ghir.2006.12.002","article-title":"Differential regulation of membrane associated-growth hormone binding protein (MA-GHBP) and growth hormone receptor (GHR) expression by growth hormone (GH) in mouse liver","volume":"17","author":"Gonz\u00e1lez","year":"2007","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.cellimm.2013.11.003_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ghir.2005.11.001","article-title":"Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects","volume":"16","author":"Fisker","year":"2006","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.cellimm.2013.11.003_b0390","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI117069","article-title":"Metabolic clearance of recombinant human growth hormone in health and chronic renal failure","volume":"93","author":"Haffner","year":"1994","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cellimm.2013.11.003_b0395","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1016\/S0021-9258(19)69476-7","article-title":"Polypeptide hormone degradation and receptor regulation are coupled to ligand internalization. A direct biochemical and morphologic demonstration","volume":"256","author":"Hizuka","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2013.11.003_b0400","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2265.2011.03977.x","article-title":"A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn\u2019s disease","volume":"74","author":"Wong","year":"2011","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0405","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1515\/JPEM.2007.20.12.1315","article-title":"Effects of recombinant human growth hormone on linear growth in children with Crohn\u2019s disease and short stature","volume":"20","author":"Wong","year":"2007","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.cellimm.2013.11.003_b0410","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0016-5085(88)90230-2","article-title":"Chronic intermittent elemental diet improves growth failure in children with Crohn\u2019s disease","volume":"94","author":"Belli","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2013.11.003_b0415","unstructured":"A. Slonim, Growth hormone and exclusion diet in Juvenile Crohn\u2019s disease. ClinicalTrials.gov. Natl. Lib. Med. (2012). Available from: <http:\/\/clinicaltrials.gov\/show\/NCT00603616> NLM Identifier: NCT01647412."},{"key":"10.1016\/j.cellimm.2013.11.003_b0420","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/07315724.2009.10719782","article-title":"Effect of exclusion diet with nutraceutical therapy in juvenile Crohn\u2019s disease","volume":"28","author":"Slonim","year":"2009","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0425","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1017\/S1466252300000049","article-title":"Conjugated linoleic acid","volume":"1","author":"O\u2019Quinn","year":"2000","journal-title":"Anim. Health Res. Rev."},{"key":"10.1016\/j.cellimm.2013.11.003_b0430","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3945\/jn.109.120527","article-title":"Individual isomers of conjugated linoleic acid reduce inflammation associated with established collagen-induced arthritis in DBA\/1 mice","volume":"140","author":"Huebner","year":"2010","journal-title":"J. Nutr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0435","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3945\/jn.109.115642","article-title":"Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPAR-gamma","volume":"140","author":"Evans","year":"2010","journal-title":"J. Nutr."},{"key":"10.1016\/j.cellimm.2013.11.003_b0440","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.iy.02.040184.002003","article-title":"The role of arachidonic acid oxygenation products in pain and inflammation","volume":"2","author":"Davies","year":"1984","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2013.11.003_b0445","doi-asserted-by":"crossref","first-page":"R908","DOI":"10.1152\/ajpregu.2001.280.3.R908","article-title":"CLA reduces antigen-induced histamine and PGE2 release from sensitized guinea pig trachaea","volume":"280","author":"Whigham","year":"2000","journal-title":"Am. J. Physiol. Regul. Integ. Comp. Physiol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874913001871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874913001871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:50:41Z","timestamp":1757803841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874913001871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":89,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0008874913001871"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2013.11.003","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crohn\u2019s disease: A review of treatment options and current research","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2013.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}